The New Futures of Diagnostic Testing

Clinical Leadership and Management Review

Volumn 14, Issue 1, 2000, Pages 26-29

  Gorman, Eileen G ^a  

^a DNA Bridges Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0347243754     PISSN: 15273954     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Poste G. Molecular medicine and information-based targeted Healthcare. Nature Biotech, 1998;16(Suppl.):19-21.
2. Willis C. 25 Cool things you wish you had...and will. FORBES ASAP, 1998;June 1:49-60.
3. Vysis Inc. Press release. April 22, 1998.
4. Business Developments: SKB, Incyte form new diagnostics firm. The BBI Newsletter, 1997;October:186-187.
5. Slamon D, Leyland-Jones B, Shak S, et al. Addition of Herceptin® (humanized anti HER2 antibody) to first line chemotherapy for HER2 overexpression metastatic breast cancer markedly increases anticancer activity: a randomized, multinational controlled phase III trial. Proc Am Soc Clin Oncol, 1998;17:98a.
6. Moore SD. Roche bets on genetic research to make it a drug leader again. Wall Street Journal, 1998;July 14:A15.
7. Gorman EG, Arentzen R, Bedzyk W, Cassidy LA. An overview of immunoassay automation. In: Price CP, Newman DJ (editors). Principles and practice of immunoassay, 2nd edition. New York: Macmillian, 1997:299-323.
8. Check W. Chipping away at conventional testing. CAP Today, 1998;12:1.
9. Kopp MU, de Mello AJ, Manz A. Chemical amplification: continuous-flow PCR on a chip. Science, 1998;280:1046-1048.
10. Roger R. High-density biochip partnership set. C&EN, 1998;July 6:6.
11. Dongré AR, Eng JK, Yates JR III. Emerging tandem-mass-spectrometry techniques for rapid identification of proteins. Trends Biotech, 1997;15:418-425.
12. Ramsay G. DNA chips: state-of-the-art. Nature Biotech, 1998;16:40-44.